Company / Depreciation & Amortization
Esperion Therapeutics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$105.0K
FY2025
5-year range
$63.0K / $500.0K
FY2021-FY2025
Trend
+66.7%
vs FY2024
Sector context
#160 of 168
Health Care
What the data says
Among 168 Health Care companies, Esperion Therapeutics, Inc. is in the top 5% for depreciation & amortization. Depreciation & Amortization returned to growth in FY2025 after 2 years of decline, reaching $105,000.
Based on SEC 10-K filings.
$105,000 in FY2025 with a 3-year CAGR of -40.6%.
Improved from $164,000 to $105,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -40.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 168This company $105.0K Sector average $212.9M
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -40.6%, indicating a declining trend.
- In FY2025, depreciation & amortization increased 66.7% year-over-year.
- Ranks #160 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $105.0K | +66.7% |
| FY2024 | $63.0K | -61.6% |
| FY2023 | $164.0K | -67.2% |
| FY2022 | $500.0K | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $265.0K | +2.7% |
| FY2017 | $258.0K | +2.4% |
| FY2016 | $252.0K | +6.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026